Titan Biotech (BOM:524717) EBIT: ₹391 Mil (TTM As of Mar. 2026)


BOM:524717 Titan Biotech Ltd BOM:524717
50 GF Score
Price ₹390.40
GF Value ₹144.21
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Titan Biotech EBIT?

Titan Biotech BOM:524717 -1.88% 50 EBIT is ₹391 Mil as of Mar. 2026. GuruFocus rates BOM:524717 with a GF Score™ of 50/100 and a GF Value™ of ₹144.21 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Titan Biotech's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹105 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹391 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Titan Biotech's annualized ROC % for the quarter that ended in Mar. 2026 was 10.61%. Titan Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 33.77%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Titan Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.42%.

Titan Biotech  (BOM:524717) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Titan Biotech's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=336.5 * ( 1 - 36.24% )/( (0 + 2022.044)/ 1 )
=214.5524/2022.044
=10.61 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2138.848 - 98.071 - ( 18.733 - max(0, 259.627 - 852.425+18.733))
=2022.044

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Titan Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=420.756/( ( (0 + max(0, 0)) + (632.518 + max(613.437, 0)) )/ 1 )
=420.756/( ( 0 + 1245.955 )/ 1 )
=420.756/1245.955
=33.77 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(228.286 + 557.691 + 47.715) - (98.071 + 0 + 122.184)
=613.437

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Titan Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=390.884/16169.081
=2.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Biotech EBIT Related Terms

Titan Biotech EBIT Historical Data

* Premium members only.

The historical data trend for Titan Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Biotech EBIT Chart

Titan Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 296.57 286.80 324.68 251.69 390.88

Titan Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.07 83.07 94.43 108.20 105.19

BOM:524717 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Titan Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Titan Biotech EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Titan Biotech's EV-to-EBIT falls into.


BOM:524717
50GF Score
Titan Biotech Ltd BOM:524717
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Titan Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹391 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹391 Mil mean?
Titan Biotech (BOM:524717) has a EBIT of ₹391 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Titan Biotech.
Is Titan Biotech's EBIT too high?
Titan Biotech's current EBIT is ₹391 Mil. Overall, Titan Biotech has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's EBIT compare to VRTX and REGN?
Titan Biotech's EBIT of ₹391 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Titan Biotech. Titan Biotech's current EBIT is ₹391 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹144.21, compared to a current price of ₹390.40 — trading 170.7% above its estimated fair value. The current EBIT is ₹391 Mil. Titan Biotech's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current EBIT is ₹391 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Titan Biotech (BOM:524717) Overvalued in 2026?

Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued. The current stock price of ₹390.40 is trading 170.7% above its estimated GF Value™ of ₹144.21. GuruFocus considers Titan Biotech to be Significantly Overvalued.

Key valuation signals for BOM:524717:

  • EBIT: ₹391 Mil
  • GF Value™: ₹144.21 vs. price of ₹390.40 (170.7% above fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Titan Biotech Business Description

Address Netaji Subhash Place, 903-909, 9th Floor, Bigjos Tower, New Delhi, IND, 110034
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
50GF Score

Get the complete analysis for BOM:524717

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹390.40
Price
₹144.21
GF Value